Insilico Medicine Coming To Xpomet Medicinale 2019
The Xpomet convention is all about presenting the innovations of the future to ensure better healthcare outcomes for everyone. A highly important part of this is the drug-discovery pipeline, finding new solutions to help prevent and even cure disease. In this spirit, we are happy to announce that Insilico Medicine will be a part of Xpomet© Medicinale© 2019. Insilico Medicine are a biotechnology and artificial intelligence company that develops an end-to-end drug discovery pipeline. They will be Xpomet on October 10 to present their latest work in modern and next-generation AI for drug discovery. Their company is based across the world, with Research and Development centres in Belgium, Russia, UK, Taiwan and Korea.
AI is the hottest new topic in the pharmaceutical industry, as it has the potential to speed up the process of discovering new drugs considerably, while reducing costs and improving compliance. Insilico Medicine are at the heart of this process, using advanced bioinformatic and deep learning techniques to tackle issues as diverse as cancer, dermatological diseases, Parkinson’s disease, Alzheimer’s, ALS, diabetes, sarcopenia and ageing. The presentation plans to focus on how artificial intelligence has advanced these processes, pointing towards a world where disease prevention can be easily attainably.
Insilico Medicine founder and CEO Alex Zhavoronkov will be present at the festival to talk about his work; speaking in the Digital Innovation segment on the main stage, Thursday morning. As he says: “The topic of AI for drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area.”